

2309#020

RULE

**Department of Health
Board of Pharmacy**

**DATA—Waiver Registration Elimination
(LAC 46:LIII.2745)**

In accordance with the provisions of the Administrative Procedure Act (R.S. 49:950 et seq.) and the Pharmacy Practice Act (R.S. 37:1161 et seq.), the Board of Pharmacy has amended §2745 of its rules relative to prescriptions. The Rule change eliminates certain requirements concerning prescriptions of Schedule III, IV, or V controlled substances for detoxification or maintenance treatment. Previously, practitioners were required under federal law to obtain a special identification number from the DEA prior to prescribing or dispensing these drugs, or were required to submit a written notice of intent to obtain such a number. LBP rules currently require that such prescriptions be accompanied by this identification number or written notice. The Rule change eliminates this requirement because federal

law no longer requires practitioners to obtain this identification number. The Rule change also corrects the Code of Federal Regulations (CFR) reference for exemption of registration for certain military personnel engaged in certain controlled substance activities. This Rule is hereby adopted on the day of promulgation.

Title 46

**PROFESSIONAL AND OCCUPATIONAL
STANDARDS**

Part LIII. Pharmacists

Chapter 27. Controlled Dangerous Substances

Subchapter F. Production, Distribution, and Utilization

§2745. Prescriptions

A. - B.3. ...

C. Manner of Issuance

1. - 2.e....

3. Repealed.

4. - 5. ...

6. An official exempted from registration under 21 CFR §1301.23 shall include on all prescriptions issued by him his branch of service or agency and his service identification number, in lieu of the registration number of the practitioner required by this Section. Each such prescription shall have the name of the officer stamped, typed, or hand printed on it, as well as the signature of the officer.

C.7. - E.3. ...

4. A practitioner may prescribe, administer or provide directly any narcotic drug listed in schedule III, IV, or V approved by the FDA specifically for use in maintenance or detoxification treatment to a narcotic dependent person if the practitioner complies with the requirements of 21 CFR.

F. - G.3.c. ...

AUTHORITY NOTE: Promulgated in accordance with R.S. 40:972.

HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 34:2149 (October 2008), amended LR 41:685 (April 2015), amended by the Department of Health, Board of Pharmacy, LR 42:1090 (July 2016), amended LR 47:1645 (November 2021), amended LR 49:1556 (September 2023).

M. Joseph Fontenot Jr.
Executive Director